Table 3. Distribution of second-, third- and fourth-line treatment regimens as well as transplants after second-line treatment and response to treatments.
|
Number of patients (%) |
||
|
Second-line treatment |
32 |
|
|
Only PI-based |
5 (15.6) |
|
|
Only IMID-based |
7 (21.8) |
|
|
PI- and IMID-based |
12 (37.5) |
|
|
PI and IMIDs + PACE |
6 (18.7) |
|
|
DRd |
1 (3.1) |
|
|
Venetoclax |
1 (3.1) |
|
|
Response to second-line treatment |
CR/VGPR |
6 (18.7)/8 (25) |
|
PR/MR |
5 (15.6)/1 (3.1) |
|
|
SD/progression |
1 (3.1)/2 (6.2) |
|
|
Unspecified |
9 (28.1) |
|
|
HSCT after second-line treatment |
19 (59.3) |
|
|
Autologous |
5 (15.6) |
|
|
Allogeneic |
11 (34.3) |
|
|
Autologous and allogeneic |
3 (9.3) |
|
|
Response after HSCT |
CR/VGPR |
5 (26.3)/6 (31.6) |
|
PR/MR |
0 (0)/0 (0) |
|
|
SD/progression |
1 (5.3)/3 (15.8) |
|
|
Unspecified |
4 (21.1) |
|
|
Third-line treatment |
16 |
|
|
Only PI-based |
2 (12.5) |
|
|
Only IMID-based |
7 (43.7) |
|
|
PI- and IMID-based |
3 (18.8) |
|
|
DVd |
2 (12.5) |
|
|
Venetoclax |
1 (6.3) |
|
|
DCEP |
1 (6.3) |
|
|
Response to third-line treatment |
CR/VGPR |
1 (6.3)/0 (0) |
|
PR/MR |
0 (0)/0 (0) |
|
|
SD/progression |
2 (12.5)/8 (50) |
|
|
Unspecified |
5 (31.2) |
|
|
Fourth-line treatment |
5 |
|
|
Only PI-based |
1 (20) |
|
|
Only IMID-based |
2 (40) |
|
|
PI- and IMID-based |
1 (20) |
|
|
DVd |
1 (20) |
|
|
Response to fourth-line treatment |
CR/VGPR |
0 (0)/0 (0) |
|
PR/MR |
1 (20)/0 (0) |
|
|
SD/progression |
1 (20)/3 (60) |
|
|
Unspecified |
0 (0) |
CR: Complete response; DCEP: dexamethasone, cyclophosphamide, etoposide, cisplatin; DRd: daratumumab, lenalidomide, dexamethasone; DVd: daratumumab, bortezomib, dexamethasone; HSCT: hematopoietic stem cell transplantation; IMID: immunomodulatory agent; MR: minimal response; PACE: cisplatin, doxorubicin, cyclophosphamide, etoposide; PI: proteasome inhibitor; PR: partial response; SD: stable disease; VGPR: very good partial response. Only PI-based: VD: Bortezomib, dexamethasone; VCD: bortezomib, cyclophosphamide, dexamethasone; KD: carfilzomib, dexamethasone; KCD: carfilzomib, cyclophosphamide, dexamethasone. Only IMID-based: RD: Lenalidomide, dexamethasone; PD: pomalidomide, dexamethasone; PCD: pomalidomide, cyclophosphamide, dexamethasone. PI- and IMID-based: VRD: Bortezomib, lenalidomide, dexamethasone; VTD: bortezomib, thalidomide, dexamethasone; IRD: ixazomib, lenalidomide, dexamethasone; KPD: carfilzomib, pomalidomide, dexamethasone; KRD: carfilzomib, lenalidomide, dexamethasone. PI and/or IMIDs + PACE: VCD or VTD + PACE.